Brokers Issue Forecasts for ImageneBio FY2025 Earnings

ImageneBio, Inc. (NASDAQ:IMA) – Research analysts at Leerink Partnrs decreased their FY2025 earnings estimates for shares of ImageneBio in a research report issued on Wednesday, November 12th. Leerink Partnrs analyst D. Risinger now anticipates that the company will earn ($6.12) per share for the year, down from their previous forecast of ($5.63). Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for ImageneBio’s current full-year earnings is ($0.91) per share. Leerink Partnrs also issued estimates for ImageneBio’s Q4 2025 earnings at ($1.61) EPS, FY2026 earnings at ($5.87) EPS, FY2027 earnings at ($3.82) EPS, FY2028 earnings at ($4.42) EPS and FY2029 earnings at ($5.54) EPS.

ImageneBio (NASDAQ:IMA) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($2.91) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.47) by ($1.44).

IMA has been the topic of several other research reports. Wall Street Zen cut ImageneBio from a “hold” rating to a “strong sell” rating in a research report on Saturday. Wedbush decreased their price target on shares of ImageneBio from $25.00 to $23.00 and set a “neutral” rating on the stock in a research note on Friday, July 25th. Zacks Research lowered shares of ImageneBio from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 29th. Leerink Partners initiated coverage on shares of ImageneBio in a research note on Friday, October 24th. They issued an “outperform” rating and a $30.00 price objective for the company. Finally, Weiss Ratings assumed coverage on shares of ImageneBio in a report on Wednesday, October 22nd. They issued a “sell (e-)” rating for the company. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $26.50.

ImageneBio Trading Down 0.9%

NASDAQ:IMA opened at $7.63 on Monday. The stock has a 50 day simple moving average of $8.19 and a 200 day simple moving average of $12.56. The stock has a market cap of $30.60 million, a P/E ratio of -0.95 and a beta of 0.42. ImageneBio has a 1-year low of $7.24 and a 1-year high of $23.28.

Institutional Trading of ImageneBio

A number of hedge funds have recently added to or reduced their stakes in IMA. BML Capital Management LLC grew its position in ImageneBio by 3.5% during the 1st quarter. BML Capital Management LLC now owns 3,710,803 shares of the company’s stock worth $4,750,000 after acquiring an additional 124,937 shares during the last quarter. Deep Track Capital LP acquired a new position in shares of ImageneBio in the 3rd quarter worth approximately $7,160,000. Blue Owl Capital Holdings LP acquired a new position in ImageneBio in the third quarter valued at $4,409,000. Atlas Venture Life Science Advisors LLC bought a new stake in ImageneBio during the third quarter valued at $3,079,000. Finally, Aldebaran Capital LLC acquired a new stake in ImageneBio during the 1st quarter worth about $317,000. Institutional investors and hedge funds own 75.00% of the company’s stock.

ImageneBio Company Profile

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025.